Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q2 2025 earnings

Reported July 9, 2025 · Before market open

Revenue$44.1MBeat by $26.5M
EPS-$0.52Beat by $0.19
Revenue estimate$17.5M
EPS estimate-$0.71

Next report

Oct 8, 2026 (In 2 weeks)
Revenue estimate$24.3M
EPS estimate-$0.60

Financials

Q2 2025

Income statement

See full
Revenue$44.1M+264%
Operating income-$48.3M+0.4%
Net income-$43.5M+2.4%
EPS (diluted)-$0.52+26.8%

Balance sheet

See full
Cash & equivalents$85.2M-27.6%
Total debt$51.9M+80.2%
Total equity$447.6M+20.7%
Total assets$591.6M+15.8%

Cash flow

See full
Operating cash flow-$63.2M-59.1%
CapEx$2.7M+38.1%
Free cash flow-$65.8M-58.1%

Valuation & ratios

Valuation

as of 05/31/25
See full
Market cap$744.82M-35.0%
Enterprise value$711.59M-32.7%
P/S8.4×-10.0×

Profitability

See full
Operating margin-260.8%-22.2pp
Net margin-234.6%-24.1pp
FCF margin-255.5%—

Returns & leverage

See full
Return on equity-50.7%-1.6pp
Debt / equity0.1×0.0×
Current ratio6.8×+1.2×

FAQ

When did Nurix Therapeutics, Inc. report Q2 2025 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q2 2025 earnings on July 9, 2025 before market open.
What were Nurix Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $44.1M and eps of $-0.52 for Q2 2025.
Did Nurix Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $17.5M by $26.5M. EPS beat the consensus estimate of $-0.71 by $0.19.
How did Nurix Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 264.3% from $12.1M a year earlier and eps grew 26.8% from $-0.71.
Where can I find Nurix Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001549595-25-000094) and the 10-Q periodic report (0001549595-25-000095) directly on SEC EDGAR. The filing index links above go to sec.gov.